文献速递治疗药物监测与药物基因组学药物不良反应与药物警戒肝肾功能剂量调整

厄他培南血药浓度与神经毒性风险的回顾性队列研究

Ertapenem blood concentration: A retrospective cohort study to analyse risk of neurotoxicity.
PubMed 文献 · Br J Clin Pharmacol · 2023-05-26

该回顾性队列研究纳入102例接受厄他培南治疗的患者,旨在评估谷浓度与神经毒性风险的关系。

核心结论

  • 在存在风险因素的患者中,测定厄他培南血浆浓度可能有助于降低神经毒性风险。

研究设计与样本

  • 回顾性研究,纳入2019年10月至2021年2月接受厄他培南治疗的患者,排除重症监护病房患者、血样采集不规范者及随访不完整者。
  • 初始队列158例,最终分析纳入102例患者。

主要发现

  • 102例患者中13例(12.7%)报告神经系统异常。

临床怎么用

  • 对存在中度肾功能不全或既往神经系统疾病史等高危患者,可考虑监测厄他培南血浆谷浓度以评估神经毒性风险。

局限性

  • 本研究为回顾性设计,排除了重症监护病房患者及血样采集不规范者,可能限制结果的普遍性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

AIMS: Several cases of ertapenem-related neurotoxicity have been published in the current literature. However, studies evaluating the ertapenem blood concentration (EBC) as a risk of these adverse events are scarce. We aimed to evaluate the relationship between the trough EBC and the risk of neurological toxicity. METHODS: This was a retrospective study, including patients who underwent ertapenem treatment between October 2019 and February 2021. We excluded patients in the critical care unit and those whose blood samples were not properly taken in order to analyse ertapenem trough concentration. We also excluded patients whose clinical follow-up was not properly realized for the entire period of ertapenem treatment. The main outcome was the presence of any suspicious neurological side effect owing to ertapenem administration and its relationship with the plasma concentration. Secondary outcomes were to identify clinical and analytical data contributing to a higher risk of neurotoxicity. RESULTS: The initial cohort comprised 158 individuals. For the final analysis we evaluated 102 patients, reporting a neurological alteration in 13/102 (12.7%). Mean trough EBC was significantly higher in patients showing neurotoxicity in comparison with those who did not (37.8 mcg mL-1 , standard deviation [SD] ± 35.7 vs. 14.6 mcg mL-1 , SD ± 15.2; P = .002). In multivariable logistic regression analysis, EBC (odds ratio [OR] = 1.07; P = .006), a moderate renal insufficiency (OR = 9.2; P = .02) and a history of previous neurologic disease (OR = 9.9; P = .02) were identified as risk factors of neurological alteration during ertapenem treatment. CONCLUSIONS: In patients at risk, determining the ertapenem plasma concentration may help to minimize the risk of neurotoxicity.

来源:Br J Clin Pharmacol,查看原文。版权归原作者所有。

引用

  1. Campany-Herrero D, Pau-Parra A, González-Moreno P, et al. Ertapenem blood concentration: A retrospective cohort study to analyse risk of neurotoxicity. Br J Clin Pharmacol. 2023. PMID: 37170398. doi:10.1111/bcp.15782

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。